Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioAtla (BCAB) EPS (Weighted Average and Diluted) (2021 - 2025)

BioAtla's EPS (Weighted Average and Diluted) history spans 5 years, with the latest figure at -$0.16 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 46.67% year-over-year to -$0.16; the TTM value through Dec 2025 reached -$1.01, up 29.86%, while the annual FY2025 figure was -$1.01, 29.86% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.16 in Q4 2025 per BCAB's latest filing, up from -$0.27 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.16 in Q4 2025 to a low of -$0.9 in Q2 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.53, with a median of -$0.58 recorded in 2023.
  • Peak YoY movement for EPS (Weighted Average and Diluted): skyrocketed 68.57% in 2024, then dropped 22.73% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.63 in 2021, then dropped by 0.0% to -$0.63 in 2022, then grew by 11.11% to -$0.56 in 2023, then skyrocketed by 46.43% to -$0.3 in 2024, then soared by 46.67% to -$0.16 in 2025.
  • Per Business Quant, the three most recent readings for BCAB's EPS (Weighted Average and Diluted) are -$0.16 (Q4 2025), -$0.27 (Q3 2025), and -$0.32 (Q2 2025).